LEADER: Liraglutide lowers CVD risk in type 2 diabetes

Liraglutide is associated with a decreased risk of cardiovascular events, compared with placebo, in individuals with type 2 diabetes, according to results from the randomized, placebo-controlled,...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news